Design opportunities for actively targeted nanoparticle vaccines.
about
Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious DiseasesEngineered nanoparticles induce cell apoptosis: potential for cancer therapyA Method for Producing Protein Nanoparticles with Applications in VaccinesEffect of interaction of magnetic nanoparticles of Fe₃O₄ and artesunate on apoptosis of K562 cellsDoxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cellsEmerging nanotechnology approaches for HIV/AIDS treatment and prevention.Application of nanotechnologies for improved immune response against infectious diseases in the developing worldTargeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigenPerorally active nanomicellar formulation of quercetin in the treatment of lung cancerThe impact of nanoparticle ligand density on dendritic-cell targeted vaccines.Advances in biomimetic regeneration of elastic matrix structures.Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugatesCancer immunotherapy and nanomedicine.Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease.Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.VLPs and particle strategies for cancer vaccines.Utilization of biodegradable polymeric materials as delivery agents in dermatologyNucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Nanotechnology for delivery of peptide nucleic acids (PNAs)Multifunctional nanoparticles for cancer immunotherapy.Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration.Adjuvanticity and toxicity of cobalt oxide nanoparticles as an alternative vaccine adjuvant.Nanoparticles for localized delivery of hyaluronan oligomers towards regenerative repair of elastic matrix.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles.Mesoporous ZnO nanocapsules for the induction of enhanced antigen-specific immunological responses.Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery.
P2860
Q26744748-5777D828-C9ED-4532-ABBD-5FF03222B073Q26750869-BA3D4B03-146E-4276-B1EA-DE43CEB0F89EQ28550575-C5885720-A499-4987-9898-343353CD07C7Q28741901-0DCC6658-5BD6-4311-985A-9F14F0C7467CQ30886810-5A05A517-9D21-4468-A47B-535BFBF17960Q33518496-1CCF21EC-5196-438A-B252-84F6C7508E70Q33819656-100DCC7F-57F5-436F-997E-0BB61F92E563Q33894321-106D2B2E-EDAD-4195-BD6D-008235A1D094Q34532116-8BB32966-A54A-4608-8EF0-483F92A03CF8Q35753059-3917AF61-5E5A-4161-A59A-84BBA66FBBBCQ36062758-9BE03281-DC44-4AFF-A666-0282D2135FF7Q36552037-064F6023-B17D-4213-8987-5CFEFE10158EQ37238542-6CD2B898-35EC-4EE6-9A84-A0AE7E864532Q37785836-B7B66F6B-A930-4276-8C59-39BFC757AD23Q37965725-8391FC07-A1AE-4DDF-8D14-0D110DF73E43Q38051671-13C6AA01-27E0-474E-BA2D-6A7B8D45AA36Q38152475-3C27DCC3-1D2B-4BAC-B932-A046BA591CAAQ38182560-FD7E5628-4983-4B48-A988-55BE27534A73Q38199151-EE1C485F-4482-4677-AD5C-0F5A492D9F33Q38296086-2FC5D694-A964-4D34-A51E-36FFDE46FF71Q38418305-BC31FB15-23B8-4581-A4BF-348E6942907EQ38692217-0D9DD23B-7B36-4E12-958D-93352B9C6CB9Q38699488-562E9622-D9C6-43B0-A510-1CC478FA1600Q38744042-D2B1F94C-AAA7-44BA-90DE-8AF2A7378150Q38761022-C7A00C5E-595A-482E-B51A-10087279A392Q38880439-80A81B1C-8C5D-4649-8820-75C53FF27A93Q39311895-A6AA3F06-3D6D-48A2-92D1-26C9FCAC0677Q39709066-121FEA23-D054-4DC5-8934-556A490ED298Q41139823-BDC09A09-FB85-4DF1-A7A2-52E593F4FECAQ47097020-3EEFE525-B743-4D41-97D1-26886FE8DF64Q49438313-4879BF03-8538-4882-B598-AEC4B53C71D0Q49946285-4C7D0FCB-0697-436D-BCB6-6E311AD4DCA9Q50226473-6EFDE955-E0C7-4C0D-98E8-888EF72FA17BQ51750508-143B49BC-AF8D-4B9D-BF2B-399F31428FF9
P2860
Design opportunities for actively targeted nanoparticle vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design opportunities for actively targeted nanoparticle vaccines.
@en
Design opportunities for actively targeted nanoparticle vaccines.
@nl
type
label
Design opportunities for actively targeted nanoparticle vaccines.
@en
Design opportunities for actively targeted nanoparticle vaccines.
@nl
prefLabel
Design opportunities for actively targeted nanoparticle vaccines.
@en
Design opportunities for actively targeted nanoparticle vaccines.
@nl
P2093
P2860
P356
P1433
P1476
Design opportunities for actively targeted nanoparticle vaccines.
@en
P2093
Ira Mellman
Michael J Caplan
Stacey L Demento
Tarek M Fahmy
W Mark Saltzman
P2860
P304
P356
10.2217/17435889.3.3.343
P577
2008-06-01T00:00:00Z